Abstract
In a multicentre controlled trial 517 patients with the clinical diagnosis of myocardial infarction within the preceding 24 hours were admitted to coronary-care units, and allocated at random to receive streptokinase followed by heparin and warfarin (264 patients) or anticoagulants only (253 patients). On retrospective analysis the groups were found to be comparable. 26 (9·8%) of those treated with streptokinase and 32 (12·6%) of those in the control group died within 3 months. This difference is not statistically significant. The results suggest that streptokinase benefits those over 60 years of age, those with a history of past infarction, and those with a Peel prognostic score over 17. Although the numbers are too small for these differences to be statistically significant the trial is continuing. There was no difference in the incidence of angina or heart-failure at 3 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
